Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136760 · ClinicalTrials.gov registry record · Phase 2
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
A Phase 2 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00136760 is a Phase 2 study that has completed, run by Brown University. The registered enrollment target is 57 participants.
The verdict
NCT00136760, a Phase 2 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.
Interventions
- DRUG Bupropion
- DRUG Contingent reinforcement plus placebo
- DRUG non-contingent reinforcement plus bupropion
- DRUG Non-contingent reinforcement plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136760
The ClinicalTrials.gov registry entry for NCT00136760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bupropion is the first listed.
NCT00136760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00136760 about?
NCT00136760 is a clinical study titled "Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia". There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.
What is the current status of trial NCT00136760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2003-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00136760?
The interventions under investigation include: Bupropion (DRUG), Contingent reinforcement plus placebo (DRUG), non-contingent reinforcement plus bupropion (DRUG), Non-contingent reinforcement plus placebo (DRUG).
Who is sponsoring clinical trial NCT00136760?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.